• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CSF1R 第 550 位色氨酸在枯否素和 CSF1R 抑制剂结合及配体诱导的结构效应中的作用。

Role of CSF1R 550th-tryptophan in kusunokinin and CSF1R inhibitor binding and ligand-induced structural effect.

机构信息

Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90100, Songkhla, Thailand.

Bioactivity Testing Center, Faculty of Medicine, Prince of Songkla University, Hat Yai, 90100, Songkhla, Thailand.

出版信息

Sci Rep. 2024 May 31;14(1):12531. doi: 10.1038/s41598-024-63505-x.

DOI:10.1038/s41598-024-63505-x
PMID:38822100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11143223/
Abstract

Binding affinity is an important factor in drug design to improve drug-target selectivity and specificity. In this study, in silico techniques based on molecular docking followed by molecular dynamics (MD) simulations were utilized to identify the key residue(s) for CSF1R binding affinity among 14 pan-tyrosine kinase inhibitors and 15 CSF1R-specific inhibitors. We found tryptophan at position 550 (W550) on the CSF1R binding site interacted with the inhibitors' aromatic ring in a π-π way that made the ligands better at binding. Upon W550-Alanine substitution (W550A), the binding affinity of trans-(-)-kusunokinin and imatinib to CSF1R was significantly decreased. However, in terms of structural features, W550 did not significantly affect overall CSF1R structure, but provided destabilizing effect upon mutation. The W550A also did not either cause ligand to change its binding site or conformational changes due to ligand binding. As a result of our findings, the π-π interaction with W550's aromatic ring could be still the choice for increasing binding affinity to CSF1R. Nevertheless, our study showed that the increasing binding to W550 of the design ligand may not ensure CSF1R specificity and inhibition since W550-ligand bound state did not induce significantly conformational change into inactive state.

摘要

结合亲和力是药物设计中提高药物靶标选择性和特异性的一个重要因素。在这项研究中,我们使用基于分子对接的计算技术,随后进行分子动力学(MD)模拟,以确定 14 种泛酪氨酸激酶抑制剂和 15 种 CSF1R 特异性抑制剂中与 CSF1R 结合亲和力相关的关键残基。我们发现 CSF1R 结合位点上的色氨酸 550 位(W550)与抑制剂的芳环以π-π相互作用,使配体更好地结合。当 W550 突变为丙氨酸(W550A)时,反式-(-)-kusunokinin 和伊马替尼与 CSF1R 的结合亲和力显著降低。然而,从结构特征来看,W550 并没有显著影响 CSF1R 的整体结构,但突变会产生不稳定的影响。W550A 也不会导致配体改变其结合位点或由于配体结合而发生构象变化。根据我们的研究结果,与 W550 的芳环形成π-π相互作用仍然是增加与 CSF1R 结合亲和力的选择。然而,我们的研究表明,设计配体与 W550 的结合增加可能并不能确保 CSF1R 的特异性和抑制作用,因为 W550-配体结合状态并没有诱导明显的构象变化进入无活性状态。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/356d88e1921f/41598_2024_63505_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/8105ed86a87f/41598_2024_63505_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/a69405378116/41598_2024_63505_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/ca3b97f057d9/41598_2024_63505_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/1c13d9f6f1e1/41598_2024_63505_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/9ea37231f0d9/41598_2024_63505_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/b1adb7a72d16/41598_2024_63505_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/f8466e57ed71/41598_2024_63505_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/356d88e1921f/41598_2024_63505_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/8105ed86a87f/41598_2024_63505_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/a69405378116/41598_2024_63505_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/ca3b97f057d9/41598_2024_63505_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/1c13d9f6f1e1/41598_2024_63505_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/9ea37231f0d9/41598_2024_63505_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/b1adb7a72d16/41598_2024_63505_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/f8466e57ed71/41598_2024_63505_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4aa1/11143223/356d88e1921f/41598_2024_63505_Fig8_HTML.jpg

相似文献

1
Role of CSF1R 550th-tryptophan in kusunokinin and CSF1R inhibitor binding and ligand-induced structural effect.CSF1R 第 550 位色氨酸在枯否素和 CSF1R 抑制剂结合及配体诱导的结构效应中的作用。
Sci Rep. 2024 May 31;14(1):12531. doi: 10.1038/s41598-024-63505-x.
2
Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation.(±)-kusunokinin 通过抑制 CSF1R 和 AKT 来阻碍乳腺癌细胞的增殖。
Biomed Pharmacother. 2020 Sep;129:110361. doi: 10.1016/j.biopha.2020.110361. Epub 2020 Jun 11.
3
Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design.使用基于片段的药物设计鉴定、合成和评估 CSF1R 抑制剂。
Comput Biol Chem. 2019 Jun;80:374-383. doi: 10.1016/j.compbiolchem.2019.04.015. Epub 2019 May 2.
4
Potential Stereoselective Binding of -(±)-Kusunokinin and -(±)-Kusunokinin Isomers to CSF1R.(±)-库苏诺菌素和(±)-库苏诺菌素异构体与 CSF1R 的潜在立体选择性结合。
Molecules. 2022 Jun 29;27(13):4194. doi: 10.3390/molecules27134194.
5
Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes.伊马替尼抑制 CSF1R,后者刺激类风湿关节炎成纤维样滑膜细胞的增殖。
Clin Exp Immunol. 2019 Feb;195(2):237-250. doi: 10.1111/cei.13220. Epub 2018 Oct 23.
6
Molecular dynamics simulations provide insights into the origin of gleevec's selectivity toward human tyrosine kinases.分子动力学模拟为格利卫(Gleevec)对人类酪氨酸激酶选择性的起源提供了深入了解。
J Biomol Struct Dyn. 2019 Jul;37(10):2733-2744. doi: 10.1080/07391102.2018.1496139. Epub 2018 Nov 1.
7
Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties.通过替换铰链结合部分发现有效的集落刺激因子 1 受体抑制剂。
Eur J Med Chem. 2021 Apr 15;216:113298. doi: 10.1016/j.ejmech.2021.113298. Epub 2021 Feb 22.
8
In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.基于 2-芳基氨基嘧啶的新型化合物的计算机设计与计算评估:作为潜在多靶点蛋白激酶抑制剂的应用,针对天然和突变(T315I)Bcr-Abl 酪氨酸激酶。
J Biomol Struct Dyn. 2023 Jun;41(9):4065-4080. doi: 10.1080/07391102.2022.2062784. Epub 2022 Apr 26.
9
targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer.集落刺激因子-1受体的靶向作用:阐明癌症免疫疗法
Explor Target Antitumor Ther. 2023;4(4):727-742. doi: 10.37349/etat.2023.00164. Epub 2023 Aug 31.
10
First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent.首个 DAPK1/CSF1R 双靶抑制剂:3,5-二甲氧基-N-(4-(4-甲氧基苯氧基)-2-((6-吗啉吡啶-3-基)氨基)嘧啶-5-基)苯甲酰胺作为一种有潜力的抗tau 病药物的发现。
Eur J Med Chem. 2019 Jan 15;162:161-175. doi: 10.1016/j.ejmech.2018.10.057. Epub 2018 Nov 2.

引用本文的文献

1
Role of Non-Binding T63 Alteration in IL-18 Binding.非结合性T63改变在白细胞介素-18结合中的作用。
Int J Mol Sci. 2024 Dec 3;25(23):12992. doi: 10.3390/ijms252312992.
2
Octanoic Acid and Decanoic Acid Inhibit Tunicamycin-Induced ER Stress in Rat Aortic Smooth Muscle Cells.辛酸和癸酸抑制衣霉素诱导的大鼠主动脉平滑肌细胞内质网应激
Adv Pharmacol Pharm Sci. 2024 Nov 26;2024:9076988. doi: 10.1155/adpp/9076988. eCollection 2024.

本文引用的文献

1
-(±)-TTPG-B Attenuates Cell Cycle Progression and Inhibits Cell Proliferation on Cholangiocarcinoma Cells.-(±)-TTPG-B 抑制胆管癌细胞周期进程并抑制细胞增殖。
Molecules. 2023 Oct 30;28(21):7342. doi: 10.3390/molecules28217342.
2
targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer.集落刺激因子-1受体的靶向作用:阐明癌症免疫疗法
Explor Target Antitumor Ther. 2023;4(4):727-742. doi: 10.37349/etat.2023.00164. Epub 2023 Aug 31.
3
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.
酪氨酸激酶抑制剂在癌症治疗中的不良反应:病理生理学、机制和临床管理。
Signal Transduct Target Ther. 2023 Jul 7;8(1):262. doi: 10.1038/s41392-023-01469-6.
4
Synthesis and Development of Highly Selective Pyrrolo[2,3-]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form.高选择性吡咯并[2,3-d]嘧啶 CSF1R 抑制剂的合成与开发:针对自动抑制形式。
J Med Chem. 2023 May 25;66(10):6959-6980. doi: 10.1021/acs.jmedchem.3c00428. Epub 2023 May 16.
5
A highly selective purine-based inhibitor of CSF1R potently inhibits osteoclast differentiation.一种高选择性的基于嘌呤的 CSF1R 抑制剂能有效抑制破骨细胞分化。
Eur J Med Chem. 2023 Jul 5;255:115344. doi: 10.1016/j.ejmech.2023.115344. Epub 2023 Apr 28.
6
Decoding the Identification Mechanism of an SAM-III Riboswitch on Ligands through Multiple Independent Gaussian-Accelerated Molecular Dynamics Simulations.通过多个独立的高斯加速分子动力学模拟解码 SAM-III 核糖开关对配体的识别机制。
J Chem Inf Model. 2022 Dec 12;62(23):6118-6132. doi: 10.1021/acs.jcim.2c00961. Epub 2022 Nov 28.
7
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.CSF1R 抑制剂是癌症治疗中新兴的免疫治疗药物。
Eur J Med Chem. 2023 Jan 5;245(Pt 1):114884. doi: 10.1016/j.ejmech.2022.114884. Epub 2022 Oct 29.
8
The use of machine learning modeling, virtual screening, molecular docking, and molecular dynamics simulations to identify potential VEGFR2 kinase inhibitors.使用机器学习建模、虚拟筛选、分子对接和分子动力学模拟来鉴定潜在的 VEGFR2 激酶抑制剂。
Sci Rep. 2022 Nov 5;12(1):18825. doi: 10.1038/s41598-022-22992-6.
9
Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.发现吡咯并[2,3-d]嘧啶衍生物作为有效和选择性集落刺激因子 1 受体激酶抑制剂。
Eur J Med Chem. 2022 Dec 5;243:114782. doi: 10.1016/j.ejmech.2022.114782. Epub 2022 Sep 21.
10
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).正在临床开发中用于治疗腱鞘巨细胞瘤 (TGCT) 的 vimseltinib(DCC-3014),一种高度选择性 CSF1R 开关控制激酶抑制剂的发现。
Bioorg Med Chem Lett. 2022 Oct 15;74:128928. doi: 10.1016/j.bmcl.2022.128928. Epub 2022 Aug 10.